Speaker Profile

PhD, Co-Founder & Chief Strategy Officer, Genetika+

Biography
Genetika+ is focused on personalizing treatment in the mental health space, with a first product focusing on optimizing drug choice in depression. Prior to co-founding Genetika+ , Daphna was Chief Scientific Officer at Ibex Medical Analytics, a digital health company developing AI-based cancer diagnostics, and before that, she served as Head, Personalized Medicine and Diagnostics at Teva Pharmaceuticals, where she supported the discovery, development and differentiation of Tevas pipeline drugs, in collaboration with the Israeli healthcare sector and multinational companies. Daphna joined Teva after having led biomarker and diagnostic development activities within the pipeline of multiple top-10 pharma and fortune 500 companies. She served in several roles with increasing responsibility at Selventa, a system's biology company focused on personalized medicine, and founded the Israeli branch of the company, as Global Head of Diagnostics. Daphna trained as post-doc at Harvard University, after receiving her PhD in Medical Sciences from the Technion.


Talk
Brain in a Dish: Personalizing Treatment in Depression


Clinical Dx Showcase:
Genetika+

Genetika+ personalizes treatment in the mental health space, initially focusing on depression. The Genetika+ platform uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

 Session Abstract – PMWC 2024 Silicon Valley

Showcase Track S2 - January 24 9.30 A.M.-1.45 P.M.,Showcase Track S2 - January 25 9.00 A.M.-4.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-2.45 P.M.


The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Neurodegenerative

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by JUL. 18TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required